Co-Authors:
De Jan Beur, S.M., Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
Streeten, E.A., Department of Medicine, University of Maryland, School of Medicine, Baltimore, MD, United States
Civelek, A.C., Department of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
McCarthy, E.F., Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, United States
Uribe, L., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, United States
Marx, S.J., Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, United States
Onobrakpeya, O., Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States
Raisz, L.G., Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States
Watts, N.B., Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH, United States
Sharon, M., Department of Medicine, Washington Hospital Center, Washington, DC, United States
Levine, M.A., Department of Pediatrics, Ilyssa Center for Molecular and Cellular Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States
Abstract:
Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.